Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibiotics

Reuters2026/08/12 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Acurx Pharmaceuticals won new patents in Japan, Mexico covering its DNA polymerase IIIC inhibitor antibiotics across compositions, use, formulations.
Expanded portfolio now includes six U.S. patents, 10 international patents covering ibezapolstat, ACX-375C program.
Ibezapolstat for C. difficile infection remains Phase 3 ready, contingent on financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY23959) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibiotics

You may also like

Crypto prices